In short
Currently, there is one ongoing clinical trial investigating treatment options for patients with recurrent or metastatic adenoid cystic carcinoma of the salivary gland. This trial is evaluating a specialized radioactive treatment that targets cancer cells directly, offering a new approach for patients whose disease has progressed or spread to other parts of the body.
Clinical trial locations
Study on the Safety and Effectiveness of Lutetium (177Lu) Vipivotide Tetraxetan for Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma
This clinical trial is investigating a targeted radioactive treatment for patients whose adenoid cystic carcinoma has come back or spread to other parts of the body. The treatment being tested is called Pluvicto, which contains a radioactive element called Lutetium-177 attached to a molecule that seeks out specific markers on cancer cells known as prostate-specific membrane antigen (PSMA). The treatment is delivered directly into a vein through an intravenous infusion.
Main inclusion criteria: To be eligible for this trial, patients must be over 18 years old and have confirmed adenoid cystic carcinoma that cannot be removed by surgery or has spread to other areas. The disease must be progressing based on imaging scans. Patients need to have a positive result on a special imaging test called 68Ga-PSMA PET/CT, which shows that their cancer cells have the PSMA marker. Adequate function of bone marrow, liver, and kidneys is required, including specific blood count levels and kidney function measurements. Women of childbearing age must have a negative pregnancy test and agree to use reliable contraception, as must men who can father children.
Main exclusion criteria: Patients with other types of cancer besides adenoid cystic carcinoma cannot participate. Those who are pregnant or breastfeeding are not eligible, as the radioactive treatment could affect the baby. Patients who have recently participated in another clinical trial may be excluded, as this could interfere with the study results. Those with certain medical conditions that could make the treatment unsafe or affect the study outcomes are also not eligible.
Focus and goal of the trial: The main goal of this study is to evaluate how well Lutetium-177 PSMA treatment works in managing adenoid cystic carcinoma that has recurred or spread. Researchers will carefully monitor patients throughout the treatment to assess both effectiveness and safety. The study follows patients through several steps: an initial assessment to confirm eligibility, administration of the treatment through intravenous infusion, regular monitoring to check for side effects and how well the cancer responds, and follow-up assessments to evaluate long-term outcomes such as progression-free survival and overall survival. Quality of life is also measured using specific questionnaires. The trial is expected to conclude by February 2028.
Investigational drug: The treatment being tested is Lutetium-177 PSMA, also known as Pluvicto. This is a specialized medication that combines a radioactive substance (Lutetium-177) with a targeting molecule that binds to PSMA markers found on certain cancer cells. By delivering radiation directly to the cancer cells, this targeted approach aims to destroy them while minimizing damage to healthy surrounding tissue. It represents a type of targeted radiotherapy that is currently being evaluated for its effectiveness, safety, and tolerability in treating this rare form of cancer.
Summary
Currently, there is one active clinical trial for adenoid cystic carcinoma of the salivary gland, taking place in Poland. This trial focuses on a novel approach using targeted radioactive therapy with Lutetium-177 PSMA, a treatment that delivers radiation directly to cancer cells that express the PSMA marker. The study specifically addresses patients with recurrent or metastatic disease, representing an important area of unmet medical need for this rare cancer type. The trial's comprehensive approach includes careful monitoring of both treatment effectiveness and patient quality of life, with results expected by 2028. This represents a promising avenue for patients whose cancer has progressed or spread beyond the original site.
